Summary by Moomoo AI
On June 3, 2024, SciClone Pharmaceuticals (stock code: 02171) published the final clinical trial results of its CAR-T cell candidate product, CT041, in the journal "Nature Medicine" and at the American Society of Clinical Oncology (ASCO) Annual Meeting. CT041 is an autologous CAR-T cell therapy targeting Claudin18.2 protein, mainly used to treat gastric cancer, esophagogastric junction adenocarcinoma, and pancreatic cancer. SciClone Pharmaceuticals stated that CT041 has shown great potential in multiple clinical trials conducted in China and North America, and has been granted the designation of "Regenerative Medicine Advanced Therapy" by the US FDA and the qualification of "Priority Medicines" by the European Medicines Agency. SciClone Pharmaceuticals is committed to innovative CAR-T cell therapies that aim to improve treatment safety, efficacy, and reduce costs, and strives to become a leader in global cancer cell therapy.